Agenus (NASDAQ:AGEN) Reaches New 12-Month Low at $8.10

Agenus Inc. (NASDAQ:AGEN - Get Free Report) reached a new 52-week low on Friday . The stock traded as low as $8.10 and last traded at $8.16, with a volume of 93931 shares. The stock had previously closed at $8.87.

Analysts Set New Price Targets

Several equities analysts have weighed in on AGEN shares. HC Wainwright reiterated a "buy" rating and set a $160.00 price objective on shares of Agenus in a research report on Thursday, March 14th. B. Riley lowered their price objective on shares of Agenus from $120.00 to $100.00 and set a "buy" rating on the stock in a research report on Monday, March 18th. Finally, StockNews.com upgraded shares of Agenus from a "sell" rating to a "hold" rating in a research report on Sunday, March 24th.

Agenus Trading Down 8.1 %

The firm's fifty day moving average price is $0.63 and its 200 day moving average price is $0.74. The firm has a market capitalization of $3.41 billion, a PE ratio of -10.24 and a beta of 1.26.

Agenus (NASDAQ:AGEN - Get Free Report) last posted its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($2.60) EPS for the quarter, missing the consensus estimate of ($0.40) by ($2.20). The firm had revenue of $83.80 million for the quarter, compared to analyst estimates of $54.21 million. As a group, research analysts expect that Agenus Inc. will post -0.41 EPS for the current year.

Insiders Place Their Bets

In other news, insider Garo H. Armen bought 25,000 shares of the business's stock in a transaction on Thursday, February 15th. The stock was purchased at an average price of $13.00 per share, with a total value of $325,000.00. Following the transaction, the insider now directly owns 31,298 shares in the company, valued at $406,874. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 4.80% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. U.S. Capital Wealth Advisors LLC acquired a new position in shares of Agenus during the first quarter valued at about $25,000. Commonwealth Equity Services LLC acquired a new position in shares of Agenus during the third quarter valued at about $26,000. Creative Planning acquired a new position in shares of Agenus during the fourth quarter valued at about $40,000. American Century Companies Inc. bought a new stake in Agenus in the fourth quarter valued at about $41,000. Finally, Sei Investments Co. bought a new stake in Agenus in the first quarter valued at about $28,000. Institutional investors and hedge funds own 61.46% of the company's stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.